- Use of Blinatumomab (Blincyto) requires participation in the Blincyto Risk Evaluation and Mitigation Strategy (REMS) program.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
- Patient information may be found in the Blinatumomab (Blincyto) package insert.
- Blinatumomab (Blincyto) patient drug information (Chemocare)
- Blinatumomab (Blincyto) patient drug information (UpToDate)
History of changes in FDA indication
- 7/1/2014: Granted FDA Breakthrough Therapy designation "for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)."
- 12/3/2014: Granted FDA accelerated approval "for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL)."
- 7/11/2017: Granted FDA regular approval "for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children."
- 3/29/2018: Granted FDA accelerated approval "for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%."
Also known as
- Code names: MT103, AMG 103
- Brand name: Blincyto